What is it about?
Increased expression of α-synuclein protein is central to the evolvement of neuropathology in Parkinson's disease (PD). The potential of ribose-cysteine and levodopa in abating α-synuclein-mediated PD was demonstrated in transgenic Drosophila model.
Featured Image
Photo by Milad Fakurian on Unsplash
Why is it important?
Long-term dopamine replacement therapy insensitivity is a drawback on levodopa. Therefore, there is a need for a product that can be used to manage the disease over a long period of time without side effects. Hence, ribose-cysteine, a glutathione booster, was explored in this study. Our findings show that ribose-cysteine and levodopa, both singly and in combination, potentiated a therapeutic effect on alpha-synuclein transgenic Drosophila melanogaster model of Parkinsonism.
Perspectives
I felt great writing this article as it offered me the opportunity to contribute to the world of neuroscience, Drosophila community and science at large. I hope it suggests a novel therapeutic approach in the management of Parkinson's disease.
Olumayowa Idowu
Osun State University, Osogbo, Nigeria
Read the Original
This page is a summary of: Ribose-cysteine and levodopa abrogate Parkinsonism via the regulation of neurochemical and redox activities in alpha-synuclein transgenic
Drosophila melanogaster
models, Fly, January 2024, Taylor & Francis,
DOI: 10.1080/19336934.2024.2306687.
You can read the full text:
Contributors
The following have contributed to this page
